Skip to main content

05 · Access & Industry

HHS to allow sale of unapproved peptides under review

The Hill Health Care1 min read

Licensed pharmacies, physicians, and federal facilities may compound the six substances after an FDA advisory panel reshaped by Secretary Robert F. Kennedy Jr. backed them.

Image from the article by The Hill Health Care: HHS to allow sale of unapproved peptides under review
Image: The Hill Health Care

After Secretary Robert F. Kennedy Jr. reshaped an FDA advisory panel that later backed six unapproved peptides, federal officials are pausing enforcement against compounding them.

A Tuesday HHS notice lets licensed pharmacies, physicians, and federal facilities make Semax, MOTS-c, KPV, Epitalon, TB-500, and BPC-157 during ongoing FDA reviews.

Despite FDA scientists finding insufficient evidence of efficacy and HHS noting potential patient risks, the agency cited strong interest in the substances.

DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾

This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.

Related context

How this story connects across the peptide landscape.